UltraClear fiber laser earns FDA clearance in two expanded indications

The FDA cleared the expanded indication of the UltraClear cold ablative fractional 2,910 nm fiber laser for treating benign pigmented lesions and vascular dyschromia. Acclaro Medical, the company behind this laser, is focused on improving treatment for pigmentation disorders by offering a more effective alternative to acids, peels, and older devices. The UltraClear laser works at a 2,910 nm wavelength, allowing for precise tissue ablation while reducing side effects like hyperpigmentation and erythema. Results on the laser’s effectiveness in treating skin conditions like aging, wrinkles, pigmentation, and scars will be presented at the Symposium for Cosmetic Advances & Laser Education.

Source link

error: Content is protected !!